KrauseDS, Van EttenRA: Tyrosine kinases as targets for cancer therapy. N Engl J Med, 2005; 353:172–187.
2.
AmirE, SerugaB, Martinez-LopezJ, et al.: Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol, 2011; 29:2543–2549.
3.
HartmannJT, HaapM, KoppHG, LippHP. Tyrosine kinase inhibitors: A review on pharmacology, metabolism and side effects. Curr Drug Metab, 2009; 10:470–481.
4.
ShahDR, ShahRR, MorganrothJ: Tyrosine kinase inhibitors: Their on-target toxicities as potential indicators of efficacy. Drug Saf, 2013; 36:413–426.
5.
ChariRVJ: Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res, 2008; 41:98–107.
6.
Mendez-VidalMJ, OrtegaEM, PinoAM, ValderramaBP, VicianR: Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev, 2012; 31:S19–S27.
7.
Thomson Reuters (Healthcare): Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Reuters (Healthcare). Last accessed August9, 2013.
8.
ShahRR, MorganrothJ, ShahDR: Cardiovascular safety of tyrosine kinase inhibitors: With a special focus on cardiac repolarisation (QT Interval). Drug Saf, 2013; 36:295–316.
9.
HuangX, PatelS, AhmedN, SeiterK, LiuD: Severe toxicity of skin rash, fever and diarrhea associated with imatinib: Case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther, 2009; 2:215–219.
10.
LipworthAD, RobertC, ZhuAX: Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology, 2009; 77:257–271.
